The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended
phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of
tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both
capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
This is a Phase 1b, open-label study of tucatinib (ONT-380) given in combination with
capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients
with HER2+ metastatic breast cancer.
Phase 1 will use a 3+3 dose escalation design to evaluate escalating dose levels of tucatinib
(ONT-380) in each of these three combinations in order to identify the maximal tolerated
dose/recommended phase 2 dose (MTD/RP2D) of tucatinib (ONT-380). Capecitabine will be given
at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a
loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days. However, a loading dose of
trastuzumab will not be given to patients who have received trastuzumab within 4 weeks of the
first study dose of trastuzumab. These patients will receive trastuzumab at 6 mg/kg each
cycle, including Cycle 1. Trastuzumab may also be given on a weekly basis at 2 mg/kg IV q 7
days, but only in the circumstance that trastuzumab infusion has been delayed, and weekly
infusions are required to resynchronize the cycle length to 21 days, after discussion with
the medical monitor. Trastuzumab infusion rates will be per institutional guidelines.
Tucatinib (ONT-380) will be given PO BID at a dose dependent upon the dosing cohorts to which
the patient is enrolled.
There will be 3-6 evaluable patients enrolled in each cohort in the dose escalation phase,
unless that dose is found to be intolerable prior to completion of enrollment. At least 6
evaluable patients are to be treated at a dose level in order for an MTD/RP2D to be
The MTD/RP2D of tucatinib (ONT-380) to be used in combination with either capecitabine alone
(Combination 1) or trastuzumab alone (Combination 2) will be determined prior to evaluating
tucatinib (ONT-380) in combination with both capecitabine and trastuzumab (Combination 3). If
Combination 1 and Combination 2 are found to be tolerable, then tucatinib (ONT-380) will be
evaluated in Combination 3, using the lowest MTD/RP2D or other SMC-recommended dose of
tucatinib (ONT-380) determined for either of the two drug combinations. This will be followed
by enrollment of an expansion cohort of patients treated at the MTD/RP2D for Combination 3.
Additional expansion cohorts for either Combination 1 (tucatinib (ONT-380) and capecitabine)
or Combination 2 (tucatinib (ONT-380) and trastuzumab) may also be enrolled.
Provided that only seven dose cohorts are needed for dose escalation and only the expansion
cohort for Combination 3 is enrolled, up to 66 evaluable patients may be enrolled. Additional
patients may be enrolled if additional expansion cohorts are opened.
Patients must meet the following criteria to be eligible for the study:
1. Metastatic breast cancer, documented as HER2+ by fluorescence in situ hybridization
(FISH) and/or 3+ staining by immunohistochemistry (IHC).
2. Progressive disease, with a history of prior treatment with both trastuzumab and T-DM1
(unless deemed intolerant to or ineligible for T-DM1 by the investigator) for
3. ≥ 18 years at time of consent.
4. If female and of child-bearing potential, has negative pregnancy test within 14 days
prior to treatment.
5. If a sexually active male or a sexually active female of child-bearing potential,
agrees to use dual (two concurrent) forms of medically accepted contraception from the
time of consent until 6 months after the last dose of ONT-380, capecitabine, or
trastuzumab, whichever is longest.
6. Signed an informed consent document that has been approved by an institutional review
board or independent ethics committee (IRB/IEC).
7. Must have target or non-target lesions as per Response Evaluation Criteria In Solid
Tumors (RECIST) 1.1.
8. All toxicity related to prior cancer therapies must have resolved to ≤ Grade 1, with
the following exceptions: alopecia; neuropathy, which must have resolved to ≤ Grade 2;
and congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the
time of occurrence and must have resolved completely.
9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.
10. In the opinion of the Investigator, life expectancy > 6 months.
11. Adequate hematologic function as defined by:
1. Hemoglobin ≥ 9 g/dL
2. Absolute neutrophil count (ANC) ≥ 1000 cells/μL
3. Platelets ≥ 100,000/μL
12. Adequate hepatic function as defined by the following:
1. Total bilirubin ≤ 1.5 X upper limit of normal (ULN), unless a known history of
2. Transaminases (aspartate aminotransferase/serum glutamic oxaloacetic transaminase
[AST/SGOT] and alanine aminotransferase/serum glutamic pyruvic transaminase
[ALT/SGPT]) ≤ 2.5 X ULN (< 5 X ULN if liver metastases are present)
13. International normalized ratio (INR) and activated partial thromboplastin time (aPTT)
≤ 1.5 X ULN unless on medication known to alter INR and aPTT.
14. Creatinine clearance ≥ 50 mL/min.
15. Left ventricular ejection fraction (LVEF) must be within institutional limits of
normal as assessed by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA)
documented within 4 weeks prior to first dose of study drug.
Patients will be excluded from the study for any of the following reasons:
1. Medical, social, or psychosocial factors that, in the opinion of the Investigator,
could impact safety or compliance with study procedures.
2. Patient is breastfeeding.
3. Previous treatment with any experimental agent within 14 days or five half-lives of
study treatment, whichever is greater.
4. Previous treatment with trastuzumab or other antibody-based therapy within three weeks
of starting study treatment or with chemotherapy or hormonal cancer therapy within two
weeks of starting study treatment.
5. Previous treatment with cumulative dose of doxorubicin > 360 mg/m2 or previous
treatment with another anthracycline with cumulative dose equivalent to > 360 mg/m2
6. Previous treatment with:
1. Capecitabine for metastatic disease at any time, for patients assigned to cohorts
using capecitabine plus ONT-380 (Combination 1) or capecitabine plus trastuzumab
plus ONT-380 (Combination 3). However, patients who have previous treatment with
capecitabine for metastatic disease are eligible for enrollment into cohorts
using trastuzumab plus ONT-380 (Combination 2). Patients who have received
capecitabine for adjuvant or neoadjuvant treatment at least 12 months prior to
starting study treatment are eligible to enroll into all cohorts (Combination 1,
2, or 3).
2. Any small molecule HER2 inhibitors including (but not limited to) lapatinib,
neratinib, or afatinib within the last 4 weeks prior to initiation of study
7. CNS disease:
1. Patients with leptomeningeal disease are excluded.
2. Dose escalation and expansion cohorts: Patients with symptomatic CNS metastases
are excluded. Patients with treated CNS metastases or untreated asymptomatic CNS
metastases not requiring immediate local therapy may be eligible. Enrollment of
patients with metastases must be approved by the study medical monitor.
3. Optional CNS disease expansion cohorts: Patients with untreated asymptomatic CNS
metastases not requiring immediate local therapy or patients with progressive CNS
disease following local therapy may be eligible with medical monitor approval.
8. History of allergic reactions to compounds of similar chemical or biological
composition to capecitabine (for patients assigned to Combination 1 or 3 only),
trastuzumab (for patients assigned to Combination 2 or 3 only), or ONT-380, except for
a history of Grade 1 or Grade 2 Infusion Related Reaction to trastuzumab, which has
been successfully managed.
9. Patients with uncorrectable electrolyte abnormalities.
10. Known to be HIV positive. HIV testing is not required for those patients who are not
known to be positive.
11. Known carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).
12. Known liver disease, autoimmune hepatitis, or sclerosing cholangitis.
13. Inability to swallow pills or any significant gastrointestinal diseases, which would
preclude adequate absorption of oral medications.
14. Use of a strong CYP3A4 inhibitor or inducer within three elimination half-lives of the
inhibitor or inducer prior to the start of study treatment.
15. Use of a strong CYP2C8 inducer or inhibitor within three elimination half-lives of the
inducer or inhibitor prior to the start of study treatment. (See Appendix F).
16. Radiotherapy within 14 days of first dose of ONT-380; patient must have recovered from
acute effects of radiotherapy to baseline.
17. Known impaired cardiac function or clinically significant cardiac disease such as
ventricular arrhythmia requiring therapy, congestive heart failure, and uncontrolled
hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood
pressure > 100 mmHg on antihypertensive medications).
18. Myocardial infarction or unstable angina within 6 months prior to the first dose of
19. Patient with known dihydropyrimidine dehydrogenase deficiency (for patients assigned
to Combination 1 or 3 only).
20. Patient requiring warfarin therapy with known history of difficulty in management of
maintaining INR within therapeutic range. Patients on warfarin may be included if on a
stable dose with a therapeutic INR.